In this project, we are seeking to identify new small molecules for clinical translation that offer neuroprotection in MS. Neurodegeneration is recognised as a key irreversible event linked to increasing disability in MS, particularly in the context of progressive forms of MS where disease progression is more consistent and treatment options more limited.

Our previous work has focused on Cu(atsm), which is part of the BTSC family of compounds and has shown early promise in providing neuroprotection in models of MS. While these outcomes have been very encouraging, emerging evidence from our group indicates that alternate BTSC compounds could offer superior benefit by more effectively modulating specific pathways targeted by Cu(atsm).

To do this, new BTSC compounds will be synthesised and screened for their effectiveness at targeting these pathways, with the most effective BTSC compounds examined for neuroprotective effects and therapeutic benefit in a progressive MS model.

In this project, we are seeking to identify new small molecules for clinical translation that offer neuroprotection in MS. Neurodegeneration is recognised as a key irreversible event linked to increasing disability in MS, particularly in the context of progressive forms of MS where disease progression is more consistent and treatment options more limited.

Our previous work has focused on Cu(atsm), [EM1.1][LM1.2]which is part of the BTSC family of compounds and has shown early promise in providing neuroprotection in models of MS. While these outcomes have been very encouraging, emerging evidence from our group indicates that alternate BTSC compounds could offer superior benefit by more effectively modulating specific pathways targeted by Cu(atsm).

To do this, new BTSC compounds will be synthesised and screened for their effectiveness at targeting these pathways, with the most effective BTSC compounds examined for neuroprotective effects and therapeutic benefit in a progressive MS model.

The main mechanisms of action for existing MS treatments involve targeting inflammation and immune responses. While these approaches have been beneficial for patients with MS, the availability of new disease-modifying therapies which target neurodegeneration associated with progression remains an unmet need.

To achieve this, an improved understanding of the most relevant contributors to neurodegeneration in MS is required alongside identification of potential treatments that best target them. Through our research, we expect to develop both a better understanding of what drives neurodegeneration in MS in addition to preclinical validation of novel therapeutic options focused on progressive MS. Successful outcomes in this regard will act as an important foundation for the translation of BTSC compounds into the clinic for progressive MS patients.

Having begun my research journey in the area of motor neurone disease, neurodegeneration and the mechanisms underpinning it has been firmly ingrained in my thinking. It was this interest that drew me into the field of MS during my Ph.D. where much remains to be elucidated on this front.

Although my project was initially focused on motor neurone disease, my curiosity around progressive MS led to work drawing striking parallels between these two distinct diseases. With this evidence, it was a natural evolution to investigate the utility of Cu(atsm) and BTSC compounds as a result of their considerable promise in the context of motor neurone disease. Jumping to the present, the prospect of being involved in bringing an effective therapeutic option to the clinic for patients with progressive MS remains a key source of inspiration.

A difficult question, with many worthy candidates. While perhaps not the most obviously exciting development, the increasingly recognised association between neurodegeneration in the grey matter areas of the spinal cord and disease progression has reinforced the parallels I've drawn with motor neurone disease, where this is a primary source of pathology.

On the treatment side, I have been closely watching the evolution of clinical data for ocrelizumab in patients with primary progressive MS. Seeing the clinical benefit has been exciting to see in terms of knowing what ‘good’ could look like in treating this form of MS, but also in terms of where further therapeutic benefit might be obtained through new disease-modifying treatment strategies that take a different approach.

Scientific research is not without its challenges, frequently having to navigate uncharted waters and patiently allowing the accumulation of evidence to guide you to what you hope will eventually be a breakthrough. However, it is exactly this type of challenge that fuels the passion and keeps you inspired on a daily basis, even in the face of setbacks along the way. Having the opportunity to be involved in an important discovery and identifying a new groundbreaking treatment for patients in the clinic is certainly the thing I enjoy the most. Being able to undertake this type of research is both meaningful and a privilege and underscores the fundamental importance of organisations like MS Australia that make it possible.

I’m not sure it counts as interesting, but away from my academic research, I like to focus on trading and investing. Although, this will be taking a back seat with the arrival of my daughter, who will unfortunately be subjected to watching the test cricket this summer (2025/26).